MOLOGEN AG (ISIN DE0006637200) has finalized a research and development, collaboration and license agreement with one of the top 10 animal health companies. The company is a division of a large, global human pharmaceutical company based in the United States. The agreement governs final clinical development, licensing, and marketing of MOLOGEN’s MIDGE-based vaccine against Leishmaniasis for a companion animal application. It is agreed to keep in confidence further contract details.
